Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis
Portal vein tumor thrombosis (PVTT) is a common phenomenon in advanced stage hepatocellular carcinoma (HCC), with a prevalence rate ranging from 10% to 60% [1]. Patients with HCC and PVTT have a dismal prognosis, with an expected survival of 2 –4 months with the best supportive care [2]. Systemic therapy with Sorafenib is the current standard treatment, recommended by the Barcelona Clinic Liver Cancer (BCLC) staging system [3,4], although, survival benefit following Sorafenib administration is modest, with a median survival time of 5. 6–8.1 months [5,6].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Seongmoon Jung, Sui Shen, Sung-Joon Ye Tags: Original paper Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | General Medicine | Hepatocellular Carcinoma | Liver | Liver Cancer | Physics | Thrombosis | Urology & Nephrology